Skip to main content

CORRECTION article

Front. Mol. Neurosci., 21 August 2020
Sec. Molecular Signalling and Pathways
Volume 13 - 2020 | https://doi.org/10.3389/fnmol.2020.00142

Corrigendum: Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R)

This article is a correction to:

  1. Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R)

    1. Read original article
\nAlexandra Fletcher-Jones &#x;Alexandra Fletcher-Jones*†Keri L. HildickKeri L. HildickAshley J. Evans&#x;Ashley J. Evans†Yasuko NakamuraYasuko NakamuraJeremy M. Henley Jeremy M. Henley*Kevin A. Wilkinson Kevin A. Wilkinson*
  • Centre for Synaptic Plasticity, School of Biochemistry, University of Bristol, Bristol, United Kingdom

A Corrigendum on
Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R)

by Fletcher-Jones, A., Hildick, K. L., Evans, A. J., Nakamura, Y., Henley, J. M., and Wilkinson, K. A. (2020). Front. Mol. Neurosci. 13:108. doi: 10.3389/fnmol.2020.00108

In the original article, we neglected to include the funders BBSRC, (BB/R00787X/1) to JH and KW and Wellcome Trust, (105384/Z/14/A) to JH and AE.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: endocannabinoid system, cannabinoid type 1 receptor, trafficking, protein-protein interactions, synaptic regulation, retrograde synaptic signaling

Citation: Fletcher-Jones A, Hildick KL, Evans AJ, Nakamura Y, Henley JM and Wilkinson KA (2020) Corrigendum: Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R). Front. Mol. Neurosci. 13:142. doi: 10.3389/fnmol.2020.00142

Received: 09 July 2020; Accepted: 13 July 2020;
Published: 21 August 2020.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2020 Fletcher-Jones, Hildick, Evans, Nakamura, Henley and Wilkinson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Alexandra Fletcher-Jones, alex.fletcher-jones@inserm.fr; Jeremy M. Henley, j.m.henley@bristol.ac.uk; Kevin A. Wilkinson, kevin.wilkinson@bristol.ac.uk

†Present address: Alexandra Fletcher-Jones, Neurocentre Magendie, INSERM 1215, Bordeaux, France
Ashley J. Evans, Drug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.